- An FDA advisory committee has voted 16-9 that there is not enough evidence to assert that the anti-inflammatory painkiller Naproxen, which Bayer (BAYRY) sells as Aleve, is safer for the heart than rival drugs.
- The vote means that Bayer and other sellers of Naproxen won't have a marketing advantage over other painkillers such as Advil, Ibuprofen and Celebrex.
- The FDA had organized the meeting after epidemiologists who work at the agency said there was evidence to show that Naproxen is safer.
FDA Panel: Naproxen not safer than other painkillers
Feb 12 2014, 08:59 ET